Online Inquiry



Call us at:

CAR T Cell Display Platform

Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs has expanded its service capabilities to offer a fully integrated CAR-T Cell Display Platform. This new platform will accelerate the timeline for cell and gene therapy development to best suit your program requirements.


Chimeric antigen receptor structure.

Chimeric antigen receptor (CAR) T cell therapies have achieved considerable progress in clinical cancer immunotherapy. However, safety challenges remain. A major problem is the response that CARs to an antigen present on healthy cells (on-target, off-tumour response). One effective strategy to improve this situation is to design the affinity of CARs so that they are activated only by tumor cells expressing high antigen levels.

CAR T cell display platform

Over years, Creative Biolabs has established a unique CAR T cell display platform that enables the engineering of variants based on antigen binding and/or signaling-based screening. By using the CRISPR-Cas9 genome editing system, we have generated an antigen-binding domain variants library with different binding affinity. Through several rounds of functional screening and deep sequencing guided selection, CAR variants selectively activated by tumor cells were distinguished based on antigen expression level. What is more, the green fluorescence reporter (GFP) reporter gene can be integrated downstream of the endogenous interleukin-2 (IL-2) gene to facilitate high-throughput screening of activated T cells by fluorescence-activated cell sorting (FACS).

The main flowchart of CAR T cell display platform.

Highlight Features

  • Our platform has several advantages to facilitate customer CAR research;
  • Having the potential to eliminate instances of toxicity early in the development of CAR-based immunotherapies;
  • Available to decouple receptor affinity and T cell activation;
  • Contribute for greater cell expansion and longer persistence.

Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing CAR-T display platform to reduce the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.


  1. Di Roberto, et al. A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. Molecular Therapy. 2020, 28,12.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

Key Updates

Receive our latest news and insights.